Retatrutide
10 mg | Vial
$120.00$50.00
Retatrutide is a next-generation investigational metabolic peptide extensively studied for its powerful fat-loss, appetite regulation, glucose metabolism optimization, and energy expenditure enhancement properties.
Developed as a triple receptor agonist, Retatrutide simultaneously activates GLP-1, GIP, and glucagon metabolic pathways, making it one of the most advanced multi-pathway compounds studied in obesity medicine, metabolic research, and longevity-focused body composition science.
Clinical research demonstrates that Retatrutide produces significant reductions in body fat mass, improves insulin sensitivity, regulates appetite signaling, and enhances metabolic efficiency, positioning it as a leading compound in modern metabolic optimization and weight-management research.
Mechanism of Action (Research-Based)
Retatrutide exerts metabolic and fat-loss effects through multi-hormonal cellular signaling, including:
Appetite & Satiety Pathway Modulation
Activates central nervous system satiety signaling to reduce hunger, improve fullness signaling, and regulate caloric intake.
Metabolic Rate & Fat Oxidation Activation
Stimulates glucagon receptor signaling pathways to increase energy expenditure and promote lipid oxidation.
Insulin & Glucose Regulation
Enhances insulin sensitivity and improves glucose metabolism through GLP-1 and GIP receptor modulation.
Gastric Emptying Regulation
Slows gastric emptying to stabilize blood sugar fluctuations and prolong satiety response.
Hormonal Energy Balance Optimization
Supports multi-pathway metabolic hormone regulation to sustain long-term body composition changes.
Outcome: Reduced appetite, progressive fat mass reduction, improved metabolic efficiency, stabilized blood sugar control, and enhanced long-term body composition optimization.
Molecular Profile
Molecular Class: Triple receptor metabolic peptide agonist
Target Receptors: GLP-1, GIP, and Glucagon receptors
Purity: ≥99% (verified via HPLC)
Storage: Lyophilized powder; stable for limited duration post-reconstitution when stored under recommended refrigeration conditions
Key Research Features
Primary Focus:
Metabolic regulation, fat-loss signaling & appetite modulation
Metabolic Activation:
Multi-pathway stimulation of fat oxidation and energy expenditure
Hormonal Regulation:
Optimizes insulin sensitivity and glucose metabolism pathways
Appetite Control:
Strong central satiety signaling modulation
Energy Utilization:
Enhances metabolic efficiency and lipid metabolism
Primary Research Applications
Fat-loss and obesity research
Metabolic syndrome and insulin resistance studies
Appetite regulation and satiety signaling research
Body composition optimization research
Glucose metabolism and endocrine signaling studies
Longevity and metabolic health research
Best For
Metabolic optimization research
Fat-loss and body composition studies
Insulin resistance and glucose regulation research
Appetite control and energy balance studies
Longevity and metabolic health protocols
Sustainable weight management research
Additional Information & Scientific Context
Retatrutide (LY3437943) is a novel, investigational "triple agonist" peptide that targets three distinct metabolic receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and GCGR (glucagon receptor). It represents the next generation of incretin-based therapy, exceeding the dual-agonist mechanisms of earlier compounds.
Preclinical models and Phase 2 human clinical trials demonstrate that Retatrutide:
Activates Triple-Hormone Pathways: Synergistically engages GLP-1 (appetite suppression), GIP (metabolic regulation/insulin sensitivity), and Glucagon (increased energy expenditure) receptors.
Induces Profound Weight Loss: Clinical data indicates weight reduction of up to 24.2% at 48 weeks, surpassing outcomes typically seen with mono- or dual-agonists.
Rapidly Reduces Liver Fat: Demonstrates potent hepatoprotective potential, with studies showing >80% reduction in liver fat content and resolution of hepatic steatosis in a significant majority of subjects.
Improves Glycemic Control: robustly lowers HbA1c levels and improves insulin sensitivity in Type 2 Diabetes models.
Modulates Lipid Profiles: Associated with improvements in blood pressure, triglycerides, and LDL cholesterol.
While mechanistic human data and Phase 2 trials strongly support these effects, Retatrutide is currently undergoing large-scale Phase 3 clinical trials (e.g., the TRIUMPH program). Therefore, it must be considered experimental.
This compound is not intended to diagnose, treat, cure, or prevent any disease.
This is not an approved medical therapy or prescription drug.
Scientific References & Research Access
Triple-Agonist Mechanism & Obesity Treatment
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial – NEJM
https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
Glycemic Control & Type 2 Diabetes
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes – The Lancet
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01053-X/fulltext
Hepatic Health & Liver Fat Reduction
Retatrutide for Metabolic Dysfunction-Associated Steatotic Liver Disease – Nature Medicine / PubMed
https://pubmed.ncbi.nlm.nih.gov/38858523/
Pharmacology & Peptide Design
Discovery of the GIP/GLP-1/Glucagon Receptor Triagonist LY3437943 (Retatrutide) – PubMed / Molecular Metabolism
https://pubmed.ncbi.nlm.nih.gov/36029941/
Intended Audience
This compound is intended for qualified researchers, clinicians, laboratory professionals, and regenerative medicine investigators conducting experimental and educational research.
Regulatory & Legal Disclaimer
This compound is supplied strictly for laboratory research and educational purposes only.
Not approved for therapeutic or medical use by CDSCO (India), FDA (USA), or EMA (EU).
This information does not replace professional medical advice.
